Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

I am seeing some signs of a Google search ranking update over the past day or so but the chatter is super limited right now. Many of the tools spike yesterday but like I said, the SEO community ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

The original version of this story appeared in Quanta Magazine. If you want to solve a tricky problem, it often helps to get organized. You might, for example, break the problem into pieces and tackle ...

Meta announced on Tuesday a new Facebook algorithm update that will showcase more Reels videos tailored to users’ preferences. The update includes features that offer users greater control over the ...

Facebook's vice president of product, Jagjit Chawla, talks about how the platform treats AI-generated content and how you can see less of it. Katelyn is a writer with CNET covering artificial ...

People’s views are becoming more and more polarized, with “echo chambers”—social bubbles that reinforce existing beliefs—exacerbating differences in opinion. This divergence doesn’t just apply to ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Researchers have used the jellyfish search algorithm to optimize solar PV distributed generation placement and sizing. They have tested the algorithm on an IEEE 33-bus system, with one, two, or three ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...